Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.
Laura C. Michaelis, MD, associate professor, Medical College of Wisconsin, discusses the integration of fedratinib (Inrebic) into the treatment paradigm of myelofibrosis.
While Michaelis has not yet used fedratinib in frontline therapy, she believes that many doctors will experience this transition period as they become more familiar with the drug and what patients will respond well to it.
Michaelis has 2 patients who have inadequate response who have progressed on ruxolitinib (Jakafi). Therefore, Michaelis is exploring treatment options, including fedratinib as a second-line therapy or enrolling them in clinical trials. The myelofibrosis field still needs to explore ruxolitinib versus fedratinib in patients with myelofibrosis, Michaelis concludes.